Published in Vaccine Weekly, November 24th, 2004
The patent, when issued, will protect a key component of Stellar's technology related to the production of keyhole limpet hemocyanin (KLH) for vaccines, and it will significantly strengthen the company's intellectual property position. Stellar is a developer of hemocyanin-based immunogenic carrier proteins for anti-cancer vaccines and other therapeutic and preventative vaccine applications.
The company's lead product, KLH, is a highly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly